Long-term progression-free-survival (PFS) under sunitinib (SU) treatment for metastatic renal cell carcinoma (Sulong study): Analysis of two populations - long term responders (LR) vs. primary refractory (PR) patients
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Fecha de publicación
2013Título de revista
EUROPEAN JOURNAL OF CANCER
Tipo de contenido
Publicación de congreso
![](/xmlui/themes/Mirage2//images/final_lines.png)